(19)
(11) EP 3 912 642 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
05.01.2022 Bulletin 2022/01

(43) Date of publication:
24.11.2021 Bulletin 2021/47

(21) Application number: 21171679.0

(22) Date of filing: 23.10.2013
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
 A61P 15/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/61; A61K 47/6889; A61K 47/6869; C07K 16/2863; A61K 47/68; A61K 47/65; A61K 47/6803; A61K 47/6845; A61P 15/00; A61P 35/00; A61K 47/6855; A61K 47/6809; A61K 47/6849; A61K 2039/505; C07K 2317/41
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 23.10.2012 EP 12189604
23.10.2012 US 201261717187 P
14.10.2013 EP 13188607

(62) Application number of the earlier application in accordance with Art. 76 EPC:
17201445.8 / 3335733
13786322.1 / 2911699

(71) Applicant: Synaffix B.V.
5349 AB Oss (NL)

(72) Inventors:
  • van Delft, Floris Louis
    6524 KZ Nijmegen (NL)
  • van Geel, Remon
    5396 CM Lithoijen (NL)
  • Wijdeven, Maria Antonia
    6603 AH Wijchen (NL)

(74) Representative: Nederlandsch Octrooibureau 
P.O. Box 29720
2502 LS The Hague
2502 LS The Hague (NL)


(56) References cited: : 
   
     
    Remarks:
    This application was filed on 30.04.2021 as a divisional application to the application mentioned under INID code 62.
    Remarks:
    Amended claims in accordance with Rule 137(2) EPC.
     


    (54) MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF


    (57) The present invention relates to an antibody comprising a GlcNAc-S(A)x substituent, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)x substituent is bonded to the antibody via C1 of the N-acetylglucosamine of said GlcNAc-S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated.
    The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1).


    The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament.
    In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.